P J Lenting

Summary

Country: France

Publications

  1. doi Regulation of von Willebrand factor-platelet interactions
    Peter J Lenting
    INSERM U 770, 80 rue du General Leclerc, 94276 Le Kremlin Bicetre, France
    Thromb Haemost 104:449-55. 2010
  2. pmc Models for prediction of factor VIII half-life in severe haemophiliacs: distinct approaches for blood group O and non-O patients
    Kathelijn Fischer
    Van Creveldkliniek, Department of Haematology, University Medical Center Utrecht, Utrecht, The Netherlands
    PLoS ONE 4:e6745. 2009
  3. ncbi Von Willebrand factor and thrombosis: risk factor, actor and pharmacological target
    Peter J Lenting
    INSERM U770 and UMR_S 770, Univ Paris Sud, 94276 Le Kremlin Bicetre, France
    Curr Vasc Pharmacol 11:448-56. 2013
  4. doi von Willebrand factor: the old, the new and the unknown
    P J Lenting
    INSERM U770, 94276 Le Kremlin Bicetre, France
    J Thromb Haemost 10:2428-37. 2012
  5. pmc Factor VIII and von Willebrand factor are ligands for the carbohydrate-receptor Siglec-5
    Julie N Pegon
    Inserm U770 Université Paris Sud, Le Kremlin Bicetre, France
    Haematologica 97:1855-63. 2012
  6. doi Identification of galectin-1 and galectin-3 as novel partners for von Willebrand factor
    Nathalie Saint-Lu
    INSERM U, Le Kremlin Bicetre, France
    Arterioscler Thromb Vasc Biol 32:894-901. 2012
  7. doi Factor VIII and von Willebrand factor--too sweet for their own good
    P J Lenting
    INSERM U 770 and Univ Paris Sud, Le Kremlin Bicetre, France
    Haemophilia 16:194-9. 2010
  8. ncbi Characterization of the interaction between von Willebrand factor and osteoprotegerin
    S Shahbazi
    INSERM U770, Le Kremlin Bicetre, F 94276, and Univ Paris Sud, Le Kremlin Bicetre, France
    J Thromb Haemost 5:1956-62. 2007
  9. ncbi Clearance mechanisms of von Willebrand factor and factor VIII
    P J Lenting
    Department of Clinical Chemistry and Haematology, Laboratory for Thrombosis and Haemostasis, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands
    J Thromb Haemost 5:1353-60. 2007
  10. doi Decreased active von Willebrand factor level owing to shear stress in aortic stenosis patients
    M J Hollestelle
    Department of Clinical Chemistry and Hematology, University Medical Center Utrecht, Utrecht, The Netherlands
    J Thromb Haemost 9:953-8. 2011

Collaborators

Detail Information

Publications26

  1. doi Regulation of von Willebrand factor-platelet interactions
    Peter J Lenting
    INSERM U 770, 80 rue du General Leclerc, 94276 Le Kremlin Bicetre, France
    Thromb Haemost 104:449-55. 2010
    ..In the present review an overview of these mechanisms will be discussed...
  2. pmc Models for prediction of factor VIII half-life in severe haemophiliacs: distinct approaches for blood group O and non-O patients
    Kathelijn Fischer
    Van Creveldkliniek, Department of Haematology, University Medical Center Utrecht, Utrecht, The Netherlands
    PLoS ONE 4:e6745. 2009
    ..Von Willebrand factor (VWF) is critical for the in vivo survival of factor VIII (FVIII). Since FVIII half-life correlates with VWF-antigen pre-infusion levels, we hypothesized that VWF levels are useful to predict FVIII half-life...
  3. ncbi Von Willebrand factor and thrombosis: risk factor, actor and pharmacological target
    Peter J Lenting
    INSERM U770 and UMR_S 770, Univ Paris Sud, 94276 Le Kremlin Bicetre, France
    Curr Vasc Pharmacol 11:448-56. 2013
    ..In the present review, an update is provided about our current knowledge on VWF as a risk factor, mediator and pharmacological target in association with thrombosis. ..
  4. doi von Willebrand factor: the old, the new and the unknown
    P J Lenting
    INSERM U770, 94276 Le Kremlin Bicetre, France
    J Thromb Haemost 10:2428-37. 2012
    ..These include angiogenesis, cell proliferation, inflammation, and tumor cell survival. In the present article, an overview of advances concerning the various structural and functional aspects of VWF will be provided...
  5. pmc Factor VIII and von Willebrand factor are ligands for the carbohydrate-receptor Siglec-5
    Julie N Pegon
    Inserm U770 Université Paris Sud, Le Kremlin Bicetre, France
    Haematologica 97:1855-63. 2012
    ..Although structurally unrelated, both share the presence of sialylated glycan-structures, making them potential ligands for sialic-acid-binding-immunoglobulin-like-lectins (Siglecs)...
  6. doi Identification of galectin-1 and galectin-3 as novel partners for von Willebrand factor
    Nathalie Saint-Lu
    INSERM U, Le Kremlin Bicetre, France
    Arterioscler Thromb Vasc Biol 32:894-901. 2012
    ..Here, we explored its interaction with the glycan-binding proteins galectin-1 and galectin-3...
  7. doi Factor VIII and von Willebrand factor--too sweet for their own good
    P J Lenting
    INSERM U 770 and Univ Paris Sud, Le Kremlin Bicetre, France
    Haemophilia 16:194-9. 2010
    ..In addition, the interaction of the FVIII/VWF complex with two families of carbohydrate-binding proteins, i.e. Galectins and Siglecs, and their potential physiological relevance will be discussed...
  8. ncbi Characterization of the interaction between von Willebrand factor and osteoprotegerin
    S Shahbazi
    INSERM U770, Le Kremlin Bicetre, F 94276, and Univ Paris Sud, Le Kremlin Bicetre, France
    J Thromb Haemost 5:1956-62. 2007
    ..The present study aimed to elucidate the molecular mechanisms underlying the interaction between OPG and VWF...
  9. ncbi Clearance mechanisms of von Willebrand factor and factor VIII
    P J Lenting
    Department of Clinical Chemistry and Haematology, Laboratory for Thrombosis and Haemostasis, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands
    J Thromb Haemost 5:1353-60. 2007
  10. doi Decreased active von Willebrand factor level owing to shear stress in aortic stenosis patients
    M J Hollestelle
    Department of Clinical Chemistry and Hematology, University Medical Center Utrecht, Utrecht, The Netherlands
    J Thromb Haemost 9:953-8. 2011
    ..To elucidate a possible role of circulating preactivated von Willebrand factor (VWF), we determined the level of VWF in its active, platelet-binding conformation in plasma of patients with aortic stenosis...
  11. doi Clearance of von Willebrand factor
    C Casari
    Unit 770, INSERM, Le Kremlin Bicetre, France UMR_S 770, Univ Paris Sud, Le Kremlin Bicetre, France
    J Thromb Haemost 11:202-11. 2013
    ....
  12. ncbi Functional mapping of anti-factor IX inhibitors developed in patients with severe hemophilia B
    O D Christophe
    INSERM U143, Hopital Bicetre, Le Kremlin Bicetre, France
    Blood 98:1416-23. 2001
    ..These data demonstrate that inhibitors appearing in patients with severe hemophilia B display specificity against restricted functional domains of factor IX...
  13. ncbi The active conformation of von Willebrand factor in patients with thrombotic thrombocytopenic purpura in remission
    E Groot
    Department of Clinical Chemistry and Haematology, University Medical Centre Utrecht, Utrecht, The Netherlands
    J Thromb Haemost 7:962-9. 2009
    ..Upon remission, however, ADAMTS13 activity does not always return to baseline...
  14. ncbi The disappearing act of factor VIII
    P J Lenting
    Laboratory for Thrombosis and Haemostasis, Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht, The Netherlands
    Haemophilia 16:6-15. 2010
    ..In the present review, focus will be on the interaction between FVIII and surface receptors that are able to capture FVIII. These interactions are of importance for FVIII, as they may affect both function and survival of FVIII...
  15. doi Clearance of von Willebrand factor
    Cecile V Denis
    INSERM U770, 80 rue du General Leclerc, 94276 Le Kremlin Bicetre Cedex, France
    Thromb Haemost 99:271-8. 2008
    ..Finally, we discuss recent data describing chemically modification of VWF as an approach to prolong the half-life of the VWF/FVIII complex...
  16. ncbi von Willebrand factor A1 domain: stuck in the middle
    P J Lenting
    Department of Clinical Chemistry and Haematology, Laboratory for Thrombosis and Haemostasis, University Medical Center Utrecht, Utrecht, The Netherlands
    J Thromb Haemost 5:1361-2. 2007
  17. ncbi Mutation and ADAMTS13-dependent modulation of disease severity in a mouse model for von Willebrand disease type 2B
    Julie Rayes
    Inserm U770 and Universite Paris Sud, Le Kremlin Bicetre, France
    Blood 115:4870-7. 2010
    ..Thus, we established a mouse model for VWD-type 2B and found that phenotype depends on mutation and ADAMTS13...
  18. ncbi Increased metastatic potential of tumor cells in von Willebrand factor-deficient mice
    V Terraube
    INSERM U143, Le Kremlin Bicetre, France
    J Thromb Haemost 4:519-26. 2006
    ..As a potential mediator of platelet-tumor cell interactions, VWF could influence this early step of tumor spread and therefore play a role in cancer metastasis...
  19. pmc Efficient inhibition of collagen-induced platelet activation and adhesion by LAIR-2, a soluble Ig-like receptor family member
    Peter J Lenting
    Institut National de la Santé et de la Recherche Médicale INSERM U770 and Univ Paris Sud, Le Kremlin Bicetre, France
    PLoS ONE 5:e12174. 2010
    ..Thus, LAIR-2/Fc has the capacity to interfere with platelet-collagen interactions mediated by Glycoprotein VI and the VWF/Glycoprotein Ib axis...
  20. ncbi P-selectin glycoprotein ligand 1 and beta2-integrins cooperate in the adhesion of leukocytes to von Willebrand factor
    Ronan Pendu
    INSERM U 770, 80 rue du General Leclerc, 94276 Le Kremlin Bicetre Cedex, France
    Blood 108:3746-52. 2006
    ..VWF is unique in its intrinsic capacity to combine the rolling and the stable adhesion step in the interaction with leukocytes...
  21. ncbi Acute activation of the endothelium results in increased levels of active von Willebrand factor in hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome
    J J J Hulstein
    Department of Haematology, University Medical Centre Utrecht, Utrecht, The Netherlands
    J Thromb Haemost 4:2569-75. 2006
    ..Activation of endothelial cells may lead to release of von Willebrand factor (VWF) multimers, which are highly reactive with platelets. Normally, newly released multimers are cleaved by ADAMTS13, resulting in less reactive derivatives...
  22. doi Towards standardization of in vivo thrombosis studies in mice
    C V Denis
    INSERM U770 UMR_S 770, Univ Paris Sud, Le Kremlin Bicêtre INSERM UMR911, Centre de Recherche en Oncologie biologique et Oncopharmacologie, Marseilles, France Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA Department of Biochemistry, Maastricht University, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands
    J Thromb Haemost 9:1641-4. 2011
    ..To cite this article: Denis CV, Dubois C, Brass LF, Heemskerk JWM, Lenting PJ, Biorheology Subcommittee of the SSC of the ISTH. Towards standardization of in vivo thrombosis studies in mice. J Thromb Haemost 2011; 9: 1641-4...
  23. doi von Willebrand factor activation, granzyme-B and thrombocytopenia in meningococcal disease
    M J Hollestelle
    Department of Clinical Chemistry and Haematology, University Medical Centre Utrecht, Utrecht, The Netherlands
    J Thromb Haemost 8:1098-106. 2010
    ..Objectives: In order to elucidate the pathophysiological mechanism behind the development of thrombocytopenia, we studied the role of von Willebrand factor (VWF) in meningococcal disease...
  24. doi Correction of bleeding symptoms in von Willebrand factor-deficient mice by liver-expressed von Willebrand factor mutants
    Isabelle Marx
    INSERM U770, 80 rue du General Leclerc, 94276 Le Kremlin Bicetre Cedex, France
    Arterioscler Thromb Vasc Biol 28:419-24. 2008
    ..To investigate the physiological importance of particular vWF domains, we have introduced mutations into murine vWF (mvWF) cDNA inhibiting vWF binding to glycoprotein (Gp) Ib, GpIIbIIIa, and to fibrillar collagen...
  25. doi Altered thrombus formation in von Willebrand factor-deficient mice expressing von Willebrand factor variants with defective binding to collagen or GPIIbIIIa
    Isabelle Marx
    Inserm U770 and Universite Paris Sud, Le Kremlin Bicetre, France
    Blood 112:603-9. 2008
    ..Our observations suggest that targeting the VWF-collagen or VWF-GPIIbIIIa interactions could be an interesting alternative for new antithrombotic strategies...